Post by icemandios on Nov 19, 2020 13:59:58 GMT
Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
MARLBOROUGH, Mass. , Nov. 19, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming 3rd Annual Evercore ISI HealthCONx Conference, which is being held virtually this year from December 1-3, 2020 .
mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Dr. Dispersyn is scheduled to participate in a fireside chat on Thursday, December 3 rd , at 3:05 p.m. ET . Interested parties may access a live webcast of the presentation at wsw.com/webcast/evercore11/phio/2360016 .
An archived version of the webcast will be made available on the " Investors – Events and Presentations " section of the Company's website after the live event.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
MARLBOROUGH, Mass. , Nov. 19, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming 3rd Annual Evercore ISI HealthCONx Conference, which is being held virtually this year from December 1-3, 2020 .
mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Dr. Dispersyn is scheduled to participate in a fireside chat on Thursday, December 3 rd , at 3:05 p.m. ET . Interested parties may access a live webcast of the presentation at wsw.com/webcast/evercore11/phio/2360016 .
An archived version of the webcast will be made available on the " Investors – Events and Presentations " section of the Company's website after the live event.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .